Back to Search
JAMES MCMULLEN, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1821848003Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.
PMID 17202264·Proc Natl Acad Sci U S A·2007
7-preclinical
PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.
PMID 17404510·Cell Cycle·2007
7-preclinical
Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.
PMID 15226426·Mol Cell Biol·2004
7-preclinical
The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway.
PMID 14597618·J Biol Chem·2004
7-preclinical
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.
PMID 15184287·Circulation·2004
7-preclinical
Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy.
PMID 14507992·Proc Natl Acad Sci U S A·2003
7-preclinical
Role of phosphoinositide 3-kinases in regulating cardiac function.
PMID 19273196·Front Biosci (Landmark Ed)·2009
6-review
Nectin-2: an intercalated disc protein that maintains cardiac function in a setting of pressure overload.
PMID 19667253·Hypertension·2009
7-preclinical
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
PMID 19679877·Am J Pathol·2009
7-preclinical
Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.
PMID 19122165·Am J Physiol Heart Circ Physiol·2009
7-preclinical
Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction.
PMID 19129376·Am J Physiol Regul Integr Comp Physiol·2009
7-preclinical
The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart.
PMID 19175355·Clin Sci (Lond)·2009
6-review
Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease.
PMID 18290876·Clin Exp Pharmacol Physiol·2008
6-review
Promoting physiological hypertrophy in the failing heart.
PMID 18307737·Clin Exp Pharmacol Physiol·2008
6-review
Acceptance versus distraction: brief instructions, metaphors and exercises in increasing tolerance for self-delivered electric shocks.
PMID 17949683·Behav Res Ther·2008
2-rct
Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism.
PMID 18267957·Cardiovasc Res·2008
7-preclinical
Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
PMID 17324134·Clin Exp Pharmacol Physiol·2007
6-review
Left ventricular hypertrophy: beyond the image and defining the human cardiac phenotype in hypertension.
PMID 17414655·J Hypertens·2007
8-other
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.
PMID 17660828·Nat Med·2007
7-preclinical
Resistin, an adipocytokine, offers protection against acute myocardial infarction.
PMID 17904155·J Mol Cell Cardiol·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 505 PARNASSUS AVE # M1480
SAN FRANCISCO, CA 94143 - Phone
- (262) 271-8602
Quick Facts
- NPI
- 1821848003
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile